405. Venture: Neurotech’s Next Billion-Dollar Breakthrough with Amy Kruse of Satori Capital

In this episode, Omar Khateeb speaks with Amy Kruse, General Partner and Chief Investment Officer at Satori Neuro, about the intersection of neuroscience, neurotechnology, AI, brain health innovation, and venture capital.A neuroscientist, DARPA leader, defense executive, entrepreneur and investor, Amy explains Satori Neuro's ecosystem approach. Interests include neuromodulation, precision psychiatry, biomarkers, digital therapeutics, psychedelics, the gut-brain axis, diagnostics and access to care.The conversation explores systems-level neuroscience and targeted interventions such as TMS, tDCS and low-intensity focused ultrasound. Amy shares how imaging, biomarkers, personalized therapies, and neuromodulation could move psychiatry toward care designed around each patient.Omar and Amy also discuss AI brain models, multimodal data, proprietary datasets, defensible platforms, brain-computer interfaces, closed-loop systems, sleep tech, consumer devices, cash-pay care, and pathways that could bring advanced treatments into homes and local clinics.For founders and investors, Amy explains clinical milestones, seed and Series A expectations, tranche financing, investor pitches, market pull, and why excellent science needs a credible commercialization strategy.DISCLAIMERThis podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.EPISODE BREAKDOWN00:00 Why Neurotechnology Is Entering a New Era00:51 Intro + Meet Amy Kruse02:57 From DARPA Neuroscience to Venture Capital07:07 Satori Neuro's Investment Thesis10:05 Market Engineering + MedTech Commercialization13:09 Precision Psychiatry and Targeted Brain Therapies16:29 AI and Foundation Models for the Brain18:27 What Creates a Defensible AI Moat?20:13 Why the US Needs to Invest in Neurotechnology22:34 The Future of Brain-Computer Interfaces25:14 Building the Next Neurotech Giant29:21 Why Neurotech Needs Platform Companies31:30 Brain-Computer Interfaces and Pharma34:14 Why Reimbursement Isn't the Only Path38:08 Bringing Neurotechnology Closer to Patients41:01 What MedTech Founders Need to Know About Fundraising44:10 What Makes an Early-Stage Startup Investable?45:49 Why Great Science Alone Isn't Enough47:14 The Biggest Founder Pitching Mistakes49:38 A Better Way to Pitch Investors53:05 The Wildest Investor Pitch Story54:30 Neuroplasticity and Neuromodulation57:49 Consumer Neurotech and Human Performance01:00:10 Why Consumer Neurotech Hasn't Exploded Yet01:01:23 The Billion-Dollar Opportunity in Sleep Tech01:03:36 Why Neurotech Form Factor Matters01:05:11 Rapid Fire + Amy's Favorite Health Tech01:07:27 The Future of Precision Brain Medicine01:08:58 Final Thoughts01:09:30 OutroAre you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.SUBSCRIBEYouTube: https://www.youtube.com/@thestateofmedtechLinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/FOLLOW THE STATE OF MEDTECHLinkedIn: https://www.linkedin.com/company/thestateofmedtech/Instagram: https://www.instagram.com/stateofmedtech/TikTok: https://www.tiktok.com/@stateofmedtechpodX: https://x.com/stateofmedtechFacebook: https://www.facebook.com/stateofmedtechFOLLOW OMAR M. KHATEEBLinkedIn: https://www.linkedin.com/in/okhateeb/Instagram: https://www.instagram.com/omar.m.khateeb/TikTok: https://www.tiktok.com/@omar.m.khateebX: https://x.com/OmarMKhateebFacebook: https://www.facebook.com/OmarMKhateeb#neurotechnology #brainhealth #neuromodulation #medtech #healthcareinnovation